Colon Cancer in Older Adults

Seminars in Oncology

Volumn 35, Issue 6, 2008, Pages 561-568

  Raftery, Laura ^a   Sanoff, Hanna Kelly ^a   Goldberg, Richard ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ARTICLE; CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; COLORECTAL CANCER; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; QUALITY OF LIFE;

AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLONIC NEOPLASMS; COMORBIDITY; GERIATRIC ASSESSMENT; HUMANS; PALLIATIVE CARE;

EID: 56249130438     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.08.004     Document Type: Article

References (46)

1. http://seer.cancer.gov/statfacts/. Accessed April 21, 2008.
2. http://ecog.dfci.harvard.edu/general/perf-stat.html.
3. Seeman T.E., Berkman L.F., Kohout F., et al. Intercommunity variations in the association between social ties and mortality in the elderly: a comparative analysis of three communities. Ann Epidemiol 3 (1993) 325-335
4. Extermann M., and Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25 (2007) 1824-1831
5. Townsley C.A., Selby R., Siu L.L., et al. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23 (2005) 3112-3124
6. Shayne M., Culakova E., Poniewierski M.S., et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 100 (2007) 1611-1620
7. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322 (1990) 352-358
8. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastasic colon cancer. J Clin Oncol 22 (2004) 23-30
9. Andre T., Boni C., Mounedju-Boudiaf L., et al. Oxaliplatin, flourouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
10. Tournigand C., André T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
11. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastasic colorectal cancer: a multicentre randomized trial. Lancet 355 (2000) 1041-1047
12. de Gramont, Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
13. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan and FU/FA with or without cituximab in the first line treatment of patients with metastasis colorectal cancer. N Engl J Med 350 (2004) 2335-2342
14. Simmonds P.D., Best L., George S., et al. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 356 (2000) 968-974
15. Sundarajan V., Mitra N., and Jacobson J.S. Survival associated with 5-flourouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136 (2002) 349-7
16. Hutchins L., Unger J., Crowley J., et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol 20 (2002) 2643-2650
17. Sundararajan V., Mitra N., Jacobson J., Hutchins L., Unger J., Crowley J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 347 (1999) 233-239
18. Schrag D., Cramer L.D., and Bach P.B. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer InstM 93 (2001) 850-857
19. Ayanian J., Zaslavsky A., Fuchs C., et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 21 (2003) 1293-1300
20. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264 (1990) 1444
21. Jessup J.M., Stewart A., Greene F.L., et al. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age and differentiation. JAMA 294 (2005) 2703-2711
22. Popescu R.A., Norman A., Ross P.J., et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years of older. J Clin Oncol 17 (1999) 2412-2418
23. Delaunoit T., Goldberg R.M., Sargent D.J., et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup trial N9741. Cancer 101 (2004) 2170-2176
24. Sargent D., Goldberg R., Jacobson S., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345 (2001) 1091-1097
25. Folrecht G., Cunningham D., Ross P., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastasis colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15 (2004) 1330-1338
26. Goldberg R.M., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24 (2006) 4085-4091
27. Rothenberg M.L., Oza A.M., Bigelow R.H., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21 (2003) 2059-2069
28. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24 (2006) 394-400
29. Figer A., Perez-Staub N., Carola E., et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 110 (2007) 2666-2671
30. Folprecht G., Seymour M.T., Saltz L., et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26 (2008) 1443-1451
31. Cunningham D., Pyrhönen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 (1998) 1413-1418
32. Sastre J., Marcuello E., Masutti B., et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. J Clin Oncol 23 (2005) 3545-3551
33. Hoff P.M., Ansari R., Batist G., et al. Comparison of oral capecitabine v intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastasis colorectal cancer: results of a randomized phase III study. J Clin Oncol 19 (2001) 2282-2292
34. Van Cutsem E., Twelves C., Cassidy J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19 (2001) 4097-4106
35. Hochster H.S., Welles L., Hart L., et al. Safety and efficacy of bevacizumab when added to oxaliplatin/fluoropyrimdine (O/F) regimens as first-line treatment of metastasis colorectal cancer: TREE 1& 2 studies [abstract]. J Clin Oncol 23 (2005) 254a
36. Feliu J., Escudero P., Llosa F., et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J Clin Oncol 23 (2005) 3104-3111
37. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007) 1232-1239
38. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (2007) 1658-1664
39. Van Cutsem E., Lang I., and D'haens G. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (MCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience [abstract]. J Clin Oncol (2008) May 20 (suppl)
40. Seymour M.T., Maughan T.S., Ledermann J.A., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370 (2007) 143-152
41. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (2007) 135-142
42. Green E., Sargent D., Goldberg R., et al. Detailed analysis of oxaliplatin-associated neuro-toxicity in Intergroup trial N9741 [abstract 182] (2005) Program and abstracts of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, Hollywood, FL, January
43. Fuchs C.S., Marshall J., and Mitchell E. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 25 (2005) 4779-4786
44. Maindrault-Goebel F., Lledo G., and Chibaudel B. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study [abstract]. J Clin Oncol 24 (2006) 18S
45. Dy G.K., Krook J.E., Green E.M., et al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol 25 (2007) 3469
46. Lièvre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26 (2008) 374-379